Answers are grounded in this paper and cite their sources.
Purpose To evaluate completion of individually tailored digital neurocognitive and symptom assessments in adults scheduled for CAR T-cell therapy and explore longitudinal changes in task-specific outcomes. Methods In this prospective single-center cohort (n = 33), NeuroCAT comprised 25 cognitive, visual, and graphomotor tasks and a symptom questionnaire at baseline (T0). At early post-infusion (T1) and pre-discharge (T2), investigators selected approximately eight tasks per participant. Results All 33 patients completed T0, and 30 (90.9%; Wilson 95% confidence interval, 76.4–96.9%) completed both T1 and T2 assessments. Two patients died before follow-up, and one did not undergo follow-up after interruption of the planned treatment pathway due to clinical instability. Paired quantitative T0/T2 observations were available for only 4-11 patients per task, with heterogeneous changes in task-specific indices and patient-reported symptoms. Among three patients with chart-documented grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS), one had increased fatigue and neuropathic pain ratings and another had increased dizziness and concentration-difficulty ratings. Nonspecific symptom worsening was also observed in patients without ICANS. Conclusion Completion of individually assigned follow-up assessments was high among enrolled patients. Nonrandom task selection, limited paired observations, unvalidated task indices, and nonspecific symptom changes preclude conclusions about ICANS detection or clinical utility. Prospective validation is required. Relevance to supportive care Tailored digital assessments may support structured symptom documentation during CAR T-cell therapy, but patient burden and clinical value remain to be established.
No takes yet. Share an insight, caveat, or question.
Fleischer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: